Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Scher, K. Fizazi, F. Saad, M. Taplin, C. Sternberg, K. Miller, R. Wit, P. Mulders, K. Chi, N. Shore, A. Armstrong, T. Flaig, A. Flechon, P. Mainwaring, M. Fleming, J. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. Bono (2012)
Increased survival with enzalutamide in prostate cancer after chemotherapy.The New England journal of medicine, 367 13
D. Castellano, L. Aparicio, E. Esteban, A. Sánchez-Hernandez, J. Germà, N. Batista, P. Maroto, B. Pérez-Valderrama, R. Luque, M. Méndez-Vidal (2014)
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access programExpert Opinion on Drug Safety, 13
J. Bono, C. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K. Chi, Robert Jones, O. Goodman, F. Saad, J. Staffurth, P. Mainwaring, S. Harland, T. Flaig, Thomas Hutson, T. Cheng, H. Patterson, J. Hainsworth, C. Ryan, C. Sternberg, S. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C. Haqq, H. Scher (2011)
Abiraterone and increased survival in metastatic prostate cancer.The New England journal of medicine, 364 21
G. Andel, A. Bottomley, S. Fosså, F. Efficace, C. Coens, S. Guérif, H. Kynaston, P. Gontero, G. Thalmann, A. Akdaş, S. D’haese, N. Aaronson (2008)
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.European journal of cancer, 44 16
P. Esper, P. Esper, P. Esper, F. Mo, F. Mo, F. Mo, G. Chodak, G. Chodak, G. Chodak, M. Sinner, M. Sinner, M. Sinner, D. Cella, D. Cella, D. Cella, K. Pienta, K. Pienta, K. Pienta (1997)
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.Urology, 50 6
W. Kelly, S. Halabi, M. Carducci, D. George, J. Mahoney, W. Stadler, M. Morris, P. Kantoff, J. Monk, E. Kaplan, N. Vogelzang, E. Small (2012)
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 13
Metastatic Castration-Resistant Prostate Cancer Treatment 173
J. Blazeby, E. Hall, N. Aaronson, Lisa Lloyd, R. Waters, J. Kelly, P. Fayers (2014)
Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder CancerEuropean Urology, 66
Heather Cheng, Heather Cheng, R. Gulati, A. Azad, R. Nadal, P. Twardowski, U. Vaishampayan, N. Agarwal, E. Heath, S. Pal, H. Rehman, A. Leiter, J. Batten, Robert Montgomery, Robert Montgomery, M. Galsky, E. Antonarakis, K. Chi, Evan Yu, Evan Yu (2014)
Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxelProstate cancer and prostatic diseases, 18
D. Berry, C. Moinpour, Caroline Jiang, D. Ankerst, D. Petrylak, L. Vinson, P. Lara, Sharon Jones, M. Taplin, P. Burch, M. Hussain, E. Crawford (2006)
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18
M. King, D. Costa, N. Aaronson, J. Brazier, D. Cella, P. Fayers, P. Grimison, M. Janda, G. Kemmler, R. Norman, R. Norman, A. Pickard, D. Rowen, G. Velikova, T. Young, R. Viney (2016)
QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30Quality of Life Research, 25
M. Nakazawa, E. Antonarakis, Jun Luo (2014)
Androgen Receptor Splice Variants in the Era of Enzalutamide and AbirateroneHormones and Cancer, 5
K. Noonan, S. North, R. Bitting, A. Armstrong, S. Ellard, K. Chi (2013)
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.Annals of oncology : official journal of the European Society for Medical Oncology, 24 7
Tian Zhang, M. Dhawan, P. Healy, D. George, M. Harrison, J. Oldan, B. Chin, A. Armstrong (2015)
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.Clinical genitourinary cancer, 13 4
O. Caffo, T. Sava, E. Comploj, A. Fariello, F. Zustovich, R. Segati, C. Sacco, A. Veccia, E. Galligioni (2011)
Impact of docetaxel‐based chemotherapy on quality of life of patients with castration‐resistant prostate cancer: results from a prospective phase II randomized trialBJU International, 108
I. Tannock, R. Wit, W. Berry, J. Horti, A. Płużańska, K. Chi, S. Oudard, C. Théodore, N. James, I. Turesson, M. Rosenthal, M. Eisenberger (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.The New England journal of medicine, 351 15
(1997)
assessment of cancer therapy-prostate instrument. Urology 1997;50:920–928
A. Bahl, S. Masson, Z. Malik, A. Birtle, S. Sundar, Robert Jones, N. James, M. Mason, Satish Kumar, D. Bottomley, A. Lydon, S. Chowdhury, J. Wylie, J. Bono (2015)
Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)BJU International, 116
T. Beer, A. Armstrong, D. Rathkopf, Y. Loriot, Cora Sternberg, C. Higano, P. Iversen, S. Bhattacharya, J. Carles, S. Chowdhury, Ian Davis, J. Bono, Christopher Evans, K. Fizazi, Anthony Joshua, Choung-Soo Kim, G. Kimura, P. Mainwaring, H. Mansbach, K. Miller, S. Noonberg, F. Perabo, D. Phung, F. Saad, H. Scher, M. Taplin, P. Venner, B. Tombal (2014)
Enzalutamide in metastatic prostate cancer before chemotherapy.The New England journal of medicine, 371 5
A. Heidenreich, P. Bastian, J. Bellmunt, M. Bolla, S. Joniau, T. Kwast, M. Mason, V. Matveev, T. Wiegel, F. Zattoni, N. Mottet (2014)
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.European urology, 65 1
S. Al-Batran, W. Hozaeel, F. Tauchert, R. Hofheinz, Axel Hinke, C. Windemuth-Kieselbach, A. Hübner, M. Burmester, M. Koenigsmann, Jörg Wiegand, G. Hausen, B. Linsse, R. Kuhl, C. Pauligk (2015)
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).Annals of oncology : official journal of the European Society for Medical Oncology, 26 6
A. Kornblith, J. Herndon, E. Zuckerman, P. Godley, D. Savarese, N. Vogelzang, J. Holland (2001)
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.Annals of oncology : official journal of the European Society for Medical Oncology, 12 5
K. Fizazi, H. Scher, A. Molina, C. Logothetis, K. Chi, Robert Jones, J. Staffurth, S. North, N. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O. Goodman, C. Sternberg, J. Li, T. Kheoh, C. Haqq, J. Bono (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.The Lancet. Oncology, 13 10
C. Ryan, Matthew Smith, K. Fizazi, F. Saad, P. Mulders, C. Sternberg, K. Miller, C. Logothetis, N. Shore, E. Small, J. Carles, T. Flaig, M. Taplin, C. Higano, P. Souza, J. Bono, T. Griffin, P. Porre, Margaret Yu, Y. Park, Jinhui Li, T. Kheoh, V. Naini, A. Molina, D. Rathkopf (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.The Lancet. Oncology, 16 2
N. James, M. Spears, N. Clarke, D. Dearnaley, J. Bono, J. Gale, J. Hetherington, Peter Hoskin, Robert Jones, R. Laing, J. Lester, D. McLaren, Christopher Parker, M. Parmar, A. Ritchie, J. Russell, R. Strebel, G. Thalmann, M. Mason, M. Sydes (2015)
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).European urology, 67 6
R. Melzack (1987)
The short-form McGill pain questionnairePain, 30
N. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N. Duez, A. Filiberti, H. Flechtner, S. Fleishman, J. Haes, S. Kaasa, M. Klee, D. Osoba, D. Razavi, Peter Rofe, S. Schraub, K. Sneeuw, M. Sullivan, F. Takeda (1993)
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.Journal of the National Cancer Institute, 85 5
J. Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. Machiels, I. Kocák, G. Gravis, I. Bodrogi, Mary Mackenzie, L. Shen, M. Roessner, Sunil Gupta, A. Sartor (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 376
Objectives: Among males, prostate cancer (PCa) is the most common cancer in Europe and the second most common cancer worldwide, especially in those aged > 70 years. With the advent of novel alternative treatments, survival in patients with advanced PCa has increased. PCa is now considered a chronic disease. Survival is an important endpoint in advanced PCa, as is quality of life (QoL). The effects of the disease and its treatment on patient health-related QoL must be taken into account when selecting the most appropriate treatment options. The present literature review aimed to provide an overview of metastatic castration-resistant prostate cancer treatment modalities, with an emphasis on side effect profiles and general health-related QoL. Methods: PubMed was searched using the keywords metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, enzalutamide, abiraterone acetate, and QoL. Conclusion: Based on the studies reviewed herein, abiraterone acetate and enzalutamide provide favorable outcomes, in terms of hematological adverse events. As enzalutamide and abiraterone acetate can be taken orally, they might have a positive effect on patient QoL.
Current Urology – Karger
Published: Jan 1, 2017
Keywords: Castration resistant prostate cancer; Docetaxel; Cabazitaxel; Enzalutamide; Abiraterone acetate; Quality of life
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.